ERBB2 and breast carcinoma: Fifty-six percent of the patients were followed for lung cancer, 13% for breast cancer (among them, 45.8% were HER2-positive), 13% for melanoma, 8.7% for cancers from the digestive tract and 4.4% for kidney cancer.